{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "15320846",
  "DateCompleted": {
    "Year": "2004",
    "Month": "11",
    "Day": "30"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "10",
    "Day": "26"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1570-1611",
      "JournalIssue": {
        "Volume": "1",
        "Issue": "2",
        "PubDate": {
          "Year": "2003",
          "Month": "Jun"
        }
      },
      "Title": "Current vascular pharmacology",
      "ISOAbbreviation": "Curr Vasc Pharmacol"
    },
    "ArticleTitle": "Diabetes, the renin-angiotensin system and heart disease.",
    "Pagination": {
      "StartPage": "225",
      "EndPage": "238",
      "MedlinePgn": "225-38"
    },
    "Abstract": {
      "AbstractText": [
        "Despite recent advances, cardiovascular disease continues to be the leading cause of death among patients with diabetes. Diabetes-related heart disease makes up the majority of the cardiovascular morbidity and mortality and this clinical entity results from synergistic interaction amongst various overlapping mechanisms. Diabetes-related heart disease is characterised by a propensity to develop premature, diffuse atherosclerotic disease, structural and functional abnormalities of the microvasculature, autonomic dysfunction and intrinsic myocardial dysfunction (the so-called diabetic 'cardiomyopathy'), all of which are exacerbated by hypertension and diabetic nephropathy. The renin-angiotensin-aldosterone system possesses various autocrine and paracrine effects which drive most of the pathophysiological mechanisms in diabetes-related heart disease. This review aims to describe the expanding role of the renin-angiotensin-aldosterone system, the complex entity of diabetes-related heart disease and the (emerging) evidence for specific inhibition of the renin-angiotensin-aldosterone system in diabetes."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University Department of Medicine, City Hospital Birmingham, England, UK."
          }
        ],
        "LastName": "Lim",
        "ForeName": "Hoong Sern",
        "Initials": "HS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Lip",
        "ForeName": "Gregory Y H",
        "Initials": "GY"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United Arab Emirates",
    "MedlineTA": "Curr Vasc Pharmacol",
    "NlmUniqueID": "101157208",
    "ISSNLinking": "1570-1611"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "epidemiology",
        "etiology",
        "physiopathology"
      ],
      "DescriptorName": "Diabetes Complications"
    },
    {
      "QualifierName": [
        "epidemiology",
        "physiopathology"
      ],
      "DescriptorName": "Diabetes Mellitus"
    },
    {
      "QualifierName": [
        "epidemiology",
        "etiology",
        "physiopathology"
      ],
      "DescriptorName": "Heart Diseases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Renin-Angiotensin System"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    }
  ],
  "NumberOfReferences": "133"
}